Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Matthew Galsky
- Target Recruit Count
- 10
- Registration Number
- NCT03359239
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 26
- Registration Number
- NCT03357224
- Locations
- 🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭UniversitaetsSpital Zurich - Division of Dermatology, Zürich, Switzerland
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 550
- Registration Number
- NCT03353831
- Locations
- 🇩🇰
Herlev University Hospital, Herlev, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷Institut Bergonié, Bordeaux, France
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 48
- Registration Number
- NCT03340376
- Locations
- 🇧🇪
UZLeuven, Leuven, Belgium
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT03337698
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
- Conditions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT03330886
- Locations
- 🇦🇷
Productos Roche S.A. Quimica e Industrial, División Farmacéutica, Buenos Aires, Argentina
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT03321643
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT03312530
- Locations
- 🇫🇷
CHU - Hôtel Dieu hematolgie clinique, Nantes, France
🇨🇿Fakultni nemocnice Ostrava; Klinika hematoonkologie, Ostrava, Czechia
🇨🇿Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT03292172
- Locations
- 🇨🇦
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇺🇸Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States
🇬🇧The Christie, Manchester, United Kingdom
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03289962
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Can Ins, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.